Urbaszek W, Graf B, Bölter C, Zingler C, Mekat A, Nabel H J, Ernst B
Abteilung für Kardiologie, Bereich Medizin der Wilhelm-Pieck-Universität Rostock.
Z Gesamte Inn Med. 1988 Nov 1;43(21):601-4.
Cardiac dysfunction and neurohumoral dysregulation show that the administration of vasodilators is reasonable in a cardiac insufficiency which is therapy-refractory against glycosides and saluretics. The alpha 1-blocker prazosin is a potent substance. On the basis of haemodynamic investigations of 55 patients the acute effects are demonstrated. Depending upon the degree of the cardiac insufficiency and the sympathetic dysregulation--measured at the behaviour of the resistance--the acute effects are convincing in more than 60% of the patients. For the long-term course patients with unequivocal initial improvement are suitable. This group can undergo a satisfactory therapy for a longer time by means of a carefully increased dosage, by corrections of the application of saluretics and by short interruptions of therapy and by the change of the dilator, respectively, or by an additional administration of another vasodilator. In the total spectre of the vasodilators which are administered in cardiac insufficiency prazosin occupies one of the first places.
心脏功能障碍和神经体液调节失调表明，在对强心苷和利尿剂治疗无效的心力衰竭中，使用血管扩张剂是合理的。α1受体阻滞剂哌唑嗪是一种有效的药物。基于对55例患者的血流动力学研究，证明了其急性效应。根据心力衰竭的程度和交感神经调节失调情况（通过阻力行为来衡量），超过60%的患者有明显的急性效应。对于长期病程，最初改善明确的患者适用。通过谨慎增加剂量、调整利尿剂的使用、短期中断治疗、更换扩张剂或额外使用另一种血管扩张剂，这组患者可以在较长时间内接受满意的治疗。在用于心力衰竭的血管扩张剂的整个范围内，哌唑嗪占据前列位置之一。
